Fig. 3From: Clinical and economic impact of ‘ROS1-testing’ strategy compared to a ‘no-ROS1-testing’ strategy in advanced NSCLC in SpainLong term cost outcomes associated to testing-ROS1 and to no-testing ROS1 strategies, base case. ROS1: c-ros oncogene 1Back to article page